FDA To Name IoM Safety Review Committee Members April 18
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
You may also be interested in...
Vioxx Re-Approval Standards Outlined In FDA Memo
Merck will need to address FDA's concerns that rofecoxib may be associated with a higher risk for cardiovascular events, the agency says in a memo outlining rationale on COX-2 inhibitors. Additional advisory committee review would be needed to consider Vioxx-specific regulatory options, FDA says.
Vioxx Re-Approval Standards Outlined In FDA Memo
Merck will need to address FDA's concerns that rofecoxib may be associated with a higher risk for cardiovascular events, the agency says in a memo outlining rationale on COX-2 inhibitors. Additional advisory committee review would be needed to consider Vioxx-specific regulatory options, FDA says.
Drug Safety Final Guidances To Be Published In March, FDA Says
FDA will publish three final guidances related to prescription drug safety in March, FDA Office of New Drugs Deputy Director Sandra Kweder said